Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma.
Karthik D NathKitsada WudhikarnAna Alarcon TomasMiguel-Angel PeralesPublished in: Expert opinion on drug safety (2023)
A thorough understanding of the toxicities associated with CD19-directed CAR T-cell therapy will facilitate the optimal selection of patients for this therapy. Furthermore, knowledge of preventative measures of CAR T-cell related complications, and early recognition and appropriate intervention will lead to the safe administration of these therapies, and ultimately improved outcomes for our patients.
Keyphrases
- end stage renal disease
- cell therapy
- ejection fraction
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- healthcare
- peritoneal dialysis
- stem cells
- diffuse large b cell lymphoma
- acute lymphoblastic leukemia
- acute myeloid leukemia
- type diabetes
- risk factors
- skeletal muscle
- multiple myeloma
- insulin resistance
- weight loss